Clinical Trials Browser

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05890352 2025-10-20

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Phase 2 Recruiting

227 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05626322 2025-09-05

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1/2 Terminated

6 enrolled 17 charts

Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07126236 2025-08-17

REPIFIR

Phase 2 Recruiting

80 enrolled

Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02763319 2025-07-17

B-MIND

Phase 2/3 Completed

453 enrolled 29 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04981795 2024-12-10

realMIND

Recruiting

100 enrolled

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04134936 2024-10-16

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Phase 1 Completed

66 enrolled 21 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Phase 2 Terminated

3 enrolled 6 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

81 enrolled 23 charts 3 FDA

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05883709 2023-06-01

A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

Unknown

15 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04300803 2020-08-28

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Approved for marketing

Lymphoid

Lymphoma, Large B-Cell, Diffuse